Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: A cross-sectional study

Archives of Medical Science

Volumn 9, Issue 5, 2013, Pages 788-795

  Filippatos, Theodosios D ^a   Rizos, Evangelos C ^a   Gazi, Irene F ^a   Lagos, Konstantinos ^a   Agouridis, Dimitrios ^a   Mikhailidis, Dimitri P ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

American Diabetes Association; Cardiovascular risk; Impaired fasting glucose; Prediabetes; Triglycerides; World Health Organization

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CARDIOVASCULAR RISK; CAUCASIAN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

EID: 84888110308     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.38671     Document Type: Article

References (28)

1. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31: 596-615.
2. Gikas A, Sotiropoulos A, Panagiotakos D, et al. Rising prevalence of diabetes among Greek adults: findings from two consecutive surveys in the same target population. Diabetes Res Clin Pract 2008; 79: 325-9.
3. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-94.
4. World Health Organization/International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a World Health Organization/International Diabetes Foundation Consultation. http://whqlibdoc.who.int/publications/2006/9241594934-eng.pdf
5. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35 Suppl. 1: S11-63.
6. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
7. Milman S, Crandall JP. Mechanisms of vascular complications in prediabetes. Med Clin North Am 2011; 95: 309-25.
8. Moutzouri E, Tsimihodimos V, Rizos E, Elisaf M. Pre-diabetes: to treat or not to treat? Eur J Pharmacol 2011; 672: 9-19.
9. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55: 1310-7.
10. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164: 2147-55. (Pubitemid 39410805)
11. Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005; 28: 2756-61. (Pubitemid 43958385)
12. DECODE Study Group, European Diabetes Epidemiology Groups. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-96.
13. D'Agostino RB Jr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-7. (Pubitemid 32640849)
14. D'Agostino RB Jr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-53. (Pubitemid 351640675)
15. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. (Pubitemid 36712275)
16. Fernandez L, Jee P, Klein MJ, Fischer P, Perkins SL, Brooks SP. A comparison of glucose concentration in paired specimens collected in serum separator and fluoride/potassium oxalate blood collection tubes under survey 'field' conditions. Clin Biochem 2013; 46: 285-8.
17. Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008; 10: 476-83. (Pubitemid 351639090)
18. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54. (Pubitemid 46768608)
19. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-80.
20. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3. (Pubitemid 351731743)
21. Aronow WS. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease? Arch Med Sci 2012; 8: 399-402.
22. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-80.
23. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
24. Rizzo M, Battista Rini G. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Med Sci 2011; 7: 5-7.
25. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother 2011; 12: 1945-58.
26. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
27. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617-21.
28. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008; 51: 264-70.